Logo
Zaloguj / Rejestruj
2020-12-09 Artykuły

Wpływ suplementacji hormonu wzrostu (GH) na wybrane czynniki modulujące ryzyko sercowo-naczyniowe

Ważnym aspektem działania hormonu wzrostu (GH) jest jego wpływ na układ sercowo-naczyniowy. Wyniki licznych badań wskazują na korzystne działanie suplementacji tego hormonu na poziom ryzyka sercowo-naczyniowego. Działanie GH na poszczególne składowe ryzyka sercowo-naczyniowego jest zróżnicowane i zależy od wielu czynników, m.in. od wieku i płci. Hormon wzrostu w układzie krążenia wywiera pozytywny, jak i negatywny wpływ.

Do pozytywnych skutków suplementacji GH można zaliczyć poprawę profilu lipidowego oraz zwiększenie masy mięśnia sercowego u chorych z niewydolnością serca. Do niekorzystnych skutków suplementacji GH zalicza się nadciśnienie oraz wzrost insulinooporności. Jednak rzadko powikłaniem suplementacji hormonu wzrostu jest cukrzyca. GH powoduje również wzrost krzepliwości krwi. Opierając się na aktualnej literaturze, nie można jednoznacznie stwierdzić, że suplementacja GH powoduje spadek ryzyka sercowo-naczyniowego. Jednak dostępne wyniki badań wskazują na prawdziwość tej hipotezy.

  Czytaj pełny tekst

Autor:  Mikołaj Czerwiński, lek. Paweł Szandrowski, dr hab. n. med., prof. UMK Michał Wiciński

Udostępnij:

Data publikacji: 2020-12-09

Źródło: "Lek w Polsce" nr 10/11/2020

Słowa kluczowe: hormon wzrostu, GH, układ krążenia, ryzyko sercowo-naczyniowe

  1. Yuen KC, Tritos NA, Samson SL, Hoffman AR, Katznelson L. American association of clinical endocrinologists and american college of endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract. 2016.
  2. Arcopinto M et al. Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. PLoS One. 2017.
  3. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011.
  4. Lithgow K, Chin A, Debert CT, Kline GA. Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion. BMC Endocr Disord. 2018.
  5. Ziagaki A, Blaschke D, Haverkamp W, Plöckinger U. Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart.  Eur J Endocrinol 2019.
  6. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008.
  7. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014.
  8. N.H. van Tilburg, F.R. Rosendaal, R.M. Bertina, Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000).
  9. Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res. 2015.
  10. Montaner J, Ribo M, Monasterio J, Molina C., AlvarezSabin J, Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003;34:1038-1040.
  11. Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, Meli R, Bruzzese D, Salerno M. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf). 2014.
  12. Wang J, Tan GJ2, Han LN1, Bai YY1, He M3, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017.
  13. Yang SH et al. Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ Open. 2017.
  14. Gao S, Zhao D, Wang M, Zhao F, Han X, Qi Y, Liu J - Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies. Can J Cardiol. 2017.
  15. Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, Yusuf S. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2016.
  16. Verhelst J, Abs R Cardiovascular risk factors in hypopituitary GH-deficient adults. Eur J Endocrinol. 2009.
  17. Birzniece V, Barrett PHR, Ho KKY. Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development. Eur J Endocrinol. 2017.
  18. Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Naoumova RP, Boroujerdi MA, Sönksen PH, Russell-Jones DL. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. J Clin Endocrinol Metab. 1999 Jan;84(1):307-16.
  19. Giagulli VA, Castellana M, Perrone R, Guastamacchia E, Iacoviello M, Triggiani V. GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis. Endocr Metab Immune Disord Drug Targets. 2017.
  20. Christ ER, Cummings MH, Jackson N, Stolinski M, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL, Umpleby AM. Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study. J Clin Endocrinol Metab. 2004.
  21. Kubo T, Furujo M, Takahashi K, Hyodo Y, Tsuchiya H, Hattori M, Fujinaga S, Urayama K. Effects of Growth Hormone Treatment on Lipid Profiles. Indian J Pediatr. 2018.
  22. Nagasaka H, Hirayama S, Takuwa M, Nakacho M, Yorifuji T, Kondou H, Miida T. ApoE4 Determines the Reduction in LDL-C After GH Replacement Therapy in Children With an Idiopathic GH Deficiency. J Clin Endocrinol Metab. 2015.
  23. Ikeda H, Kudo M. Long-term follow-up results of growth hormone therapy for patients with adult growth hormone deficiency. Hormones (Athens). 2016 Jan-Mar;15(1):45-53.
  24. Newman CB, Carmichael JD, Kleinberg DL. Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary. 2015.
  25. van Bunderen CC, van den Dries CJ, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. Eur J Endocrinol. 2014.
  26. Dullaart RP et al. HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C>A) and modified by glucocorticoid treatment. Eur J Endocrinol. 2010.
  27. Bänsch D1, Dirkes-Kersting A, Schulte H, Assmann G, von Eckardstein A. Basal growth hormone levels are positively correlated with high-density lipoprotein cholesterol levels in women. Metabolism. 1997.
  28. Kim JH, Cho JH, Yoo HW, Choi JH. Efficacy of growth hormone therapy in adults with childhood-onset growth hormone deficiency. Ann Pediatr Endocrinol Metab. 2014.
  29. Lind S et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):349-56.
  30. Horikawa R, Tanaka T, Nishinaga H, Ogawa Y, Yokoya S. The influence of a long-term growth hormone treatment on lipid and glucose metabolism: a randomized trial in short Japanese children born small for gestational age. Int J Pediatr Endocrinol. 2016.
  31. Lowe G, Rumley A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us? Thromb Haemost. 2014 Nov;112(5):860-7. doi: 10.1160/TH14-03-0199.
  32. Drouet L, Bal dit Sollier C. Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events? Mar-Apr 2005;60(2):137-47.
  33. Ravnskov U, de Lorgeril M, Kendrick M, Diamond DM. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Med Hypotheses. 2018 .
  34. Pieters M, Boshuizen H, de Lange Z, Schutte AE, Schutte R, Greeff M, Ariëns RA. Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans. 2013.
  35. Di Minno MN, Pezzullo S, Palmieri V, Di Somma C, Lupoli R, Valle D, Lombardi G, Di Minno GM. Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. Thromb Res. 2010.
  36. Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost. 1996.
  37. Cañete R1, Valle M, Martos R, Sánchez-Carrión A, Cañete MD, van Donkelaar EL. Short-term effects of GH treatment on coagulation, fibrinolysis, inflammation biomarkers, and insulin resistance status in prepubertal children with GH deficiency. Eur J Endocrinol. 2012.
  38. Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK. Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1446-1452.
  39. Carratala A, Martinez-Hervas S, Rodriguez-Borja E, Benito E, Real JT, Saez GT, Carmena R, Ascaso JF. PAI-1 levels are related to insulin resistance and carotid atherosclerosis in subjects with familial combined hyperlipidemia. J Investig Med. 2018 Jan;66(1):17-21.
  40. Alessi MC, Juhan-Vague. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2200-7.
  41. Yamamoto K, Takeshita K, Saito H. Plasminogen activator inhibitor-1 in aging. Semin Thromb Hemost. 2014 Sep;40(6):652-9.
  42. Cakir I, Tanriverdi F, Karaca Z, Kaynar L, Eser B, Unluhizarci K, Kelestimur F. Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm IGF Res. 2012.
  43. Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine. 2008.
  44. E. Rooth, H. Wallen, A. Antovic, M. von Arbin, G. Kaponides, N. Wahlgren, M. Blomba ¨ck, J. Antovic, Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul. Fibrinolysis (2007).
  45. Appiah D, Schreiner PJ, MacLehose RF, et al. Association of plasma gamma' fibrinogen with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC)study. Arterioscler Thromb Vasc Biol 2015.
  46. Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome. J Cardiovasc Pharmacol Ther. 2017.
  47. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 2017.
  48. Miljić D, Popovic V. Metabolic Syndrome in Hypopituitarism. Front Horm Res. 2018.
  49. Verhelst J, Mattsson AF, Camacho-Hübner C, Luger A, Abs R. The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis. Endocr Connect. 2018.
  50. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010.
  51. Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab. 1997.
  52. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf). 2005.
  53. Ekman B, Lindstrom,T. Nystrom F, Olsson AG, Toss, G. & Arnqvist, HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. European Journal of Endocrinology. 2002.
  54. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem. 1998.
  55. van Haeften TW, & Twickler TB. Insulin-like growth factors and pancreas beta cells. European Journal of Clinical Investigation. 2004.
  56. Angelin B, Rudling M. Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol. 1994; 5:160–165.
  57. Wong JH, Dukes J, Levy RE, Sos B, Mason SE, Fong TS, Weiss EJ. Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns. J Clin Invest. 2008.
  58. Holloway MG., Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology. 2007.
  59. Holloway MG, Laz EV, Waxman DJ. Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol Endocrinol. 2006.
  60. Monson JP, Jönsson P, Koltowska-Häggström M, Kourides I. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf). 2007.
  61. Gomes-Santos E, Salvatori R, Ferrão TO, Oliveira CRP, Diniz RDCA, Santana JAM, et al. Increased Visceral Adiposity and Cortisol to Cortisone Ratio in Adults With Congenital Lifetime Isolated GH Deficiency. J Clin Endocrinol Metab. 2014.
  62. Garmes HM, Castillo AR. Insulin signaling in the whole spectrum of GH deficiency. Arch Endocrinol Metab. 2019.
  63. Kim SH, Park MJ.  Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017.
  64. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002.
  65. Olarescu NC, Bollerslev J. The Impact of Adipose Tissue on Insulin Resistance in Acromegaly. Trends Endocrinol Metab. 2016.
  66. Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res. 2015.
  67. Weber MM, Biller BM, Pedersen BT, Pournara E, Christiansen JS, Höybye C. The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet® International Outcome Study.  Clin Endocrinol (Oxf). 2017.
  68. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf). 2004.
  69. Fedrizzi D, Rodrigues TC, Costenaro F, Scalco R, Czepielewski MA. Hypertension-related factors in patients with active and inactive acromegaly. Arq Bras Endocrinol Metabol. 2011.
  70. Ohtsuka H, Komiya I, Aizawa T, Yamada T. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J. 1995.
  71. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001.
reklama banery wege 1200x300 2023